PDCD1 and hypothyroidism: Immune checkpoint inhibitor-related diabetes ketoacidosis (ICI-DKA) and hypothyroidism are rare but serious adverse events of Anti-programmed cell death-1 (anti-PD-1) therapy, previously unreported in patients with EAC receiving tislelizumab.